{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:28:42Z","timestamp":1774484922365,"version":"3.50.1"},"reference-count":60,"publisher":"Informa UK Limited","issue":"1-2","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration"],"published-print":{"date-parts":[[2025,1,2]]},"DOI":"10.1080\/21678421.2024.2400522","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T13:53:00Z","timestamp":1725976380000},"page":"48-57","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["A scoping review of the role of managed entry agreements in upcoming drugs for amyotrophic lateral sclerosis: learning from the case of spinal muscular atrophy"],"prefix":"10.1080","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4458-2711","authenticated-orcid":false,"given":"Beliu","family":"Garc\u00eda-Parra","sequence":"first","affiliation":[{"name":"Clinical Neurophysiology Section \u2013 Neurology Service, Bellvitge University Hospital, L\u2019Hospitalet de Llobregat, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep M.","family":"Guiu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Pharmaceutical Technology, and Physical Chemistry, Faculty of Pharmacy and Food Sciences, Clinical Pharmacy and Pharmaceutical Care Unit, University of Barcelona, Barcelona, Spain, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00d3nica","family":"Povedano","sequence":"additional","affiliation":[{"name":"Clinical Neurophysiology Section \u2013 Neurology Service, Bellvitge University Hospital, L\u2019Hospitalet de Llobregat, Barcelona, Spain"},{"name":"Motor Neuron Diseases Unit, Bellvitge University Hospital, L\u2019Hospitalet de Llobregat, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Modamio","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Pharmaceutical Technology, and Physical Chemistry, Faculty of Pharmacy and Food Sciences, Clinical Pharmacy and Pharmaceutical Care Unit, University of Barcelona, Barcelona, Spain, and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2024,9,10]]},"reference":[{"key":"e_1_3_4_2_1","volume-title":"GeneReviews\u00ae","author":"Prior TW","year":"2000","unstructured":"Prior TW, Leach ME, Finanger E. Spinal muscular atrophy. In: Adam MP, Feldman J, Mirzaa GM, et\u00a0al. eds. GeneReviews\u00ae. Seattle, WA: University of Washington, Seattle; 2000."},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/cne.23917"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14393"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2016.182"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.37765\/ajmc.2021.88592"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1054006"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12101601"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114378"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.37765\/ajmc.2023.89389"},{"key":"e_1_3_4_11_1","unstructured":"European Medicines Agency. Science medicines health. Qalsody. Tofersen. 2024. Available at: www.ema.europa.eu\/en\/medicines\/human\/EPAR\/qalsody. Accessed March 4 2024."},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1916945"},{"key":"e_1_3_4_13_1","unstructured":"U.S. Food & Drug Administration. September 7 2022: Meeting of the Peripheral and Central Nervous System Drugs Advisory Committee Meeting Announcement 2022. Available at: www.fda.gov\/advisory-committees\/advisory-committee-calendar\/september-7-2022-meeting-peripheral-and-central-nervous-system-drugs-advisory-committee-meeting. Accessed January 31 2024."},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-022-00945-x"},{"key":"e_1_3_4_15_1","unstructured":"EU\/3\/20\/2284 \u2013 orphan designation for treatment of amyotrophic lateral sclerosis; 2024. Available at: www.ema.europa.eu\/en\/medicines\/human\/orphan-designations\/eu-3-20-2284. Accessed January 31 2024."},{"key":"e_1_3_4_16_1","unstructured":"Amylyx pharmaceuticals announces completion of enrollment in global phase 3 phoenix trial of AMX0035 in ALS; 2024. Available at: www.investors.amylyx.com\/news-releases\/news-release-details\/amylyx-pharmaceuticals-announces-completion-enrollment-global. Accessed January 31 2024."},{"key":"e_1_3_4_17_1","unstructured":"Biopharmadive. Amylyx ALS drug fails crucial study putting company\u2019s future in doubt; 2024. Available at: www.biopharmadive.com\/news\/amylyx-als-drug-relyvrio-fails-phoenix\/709704\/. Accessed March 30 2024."},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-024-01371-1"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3275"},{"key":"e_1_3_4_20_1","first-page":"1392","article-title":"Rising drug costs for neurologic diseases","volume":"26","author":"Crowell JL","year":"2020","unstructured":"Crowell JL, Burns TM. Rising drug costs for neurologic diseases. Continuum. 2020;26:1392\u2013406.","journal-title":"Continuum"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27015"},{"key":"e_1_3_4_22_1","unstructured":"Wenzl M Chapman S. Performance-based managed entry agreements for new medicines in OECD countries and EU member states: how they work and possible improvements going forward. OECD Health Work Paper; 2019."},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14425"},{"key":"e_1_3_4_24_1","unstructured":"NewsRARE. Modelos innovadores de financiaci\u00f3n en el campo de las EERR: de d\u00f3nde venimos y hacia d\u00f3nde vamos; 2024. Available at: https:\/\/newsrare.es\/articulos\/en-profundidad\/modelos-innovadores-de-financiacion-en-el-campo-de-las-eerr-de-donde-venimos-y-hacia-donde-vamos\/. Accessed February 14 2024."},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2022.12.014"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(22)00057-3"},{"key":"e_1_3_4_27_1","unstructured":"CMS.gov. Centers for Medicare & Medicaid Services. Alternative Payment Models (APMs); 2024. Available at: www.cms.gov\/priorities\/innovation\/key-concepts\/alternative-payment-models-apms. Accessed February 14 2024."},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.2217\/rme-2020-0169"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.01.012"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.7326\/M18-0850"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.750742"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-021-01050-5"},{"key":"e_1_3_4_33_1","unstructured":"Budget impact analysis with and without performance-based managed entry agreement of different treatments for spinal muscular atrophy (SMA) in the Kingdom of Saudi Arabia. ISPOR. ISPOR Europe; 2023. Available at: www.ispor.org\/docs\/default-source\/euro2023\/isporeurope23ojeilee97poster129910-pdf.pdf?sfvrsn=2866b897_0. Accessed April 4 2024."},{"key":"e_1_3_4_34_1","unstructured":"Ministerio de Sanidad. Protocolo cl\u00ednico de uso de Nusinersen y Risdiplam para la Atrofia Muscular Espinal (AME) en el Sistema Nacional de Salud; 2024. Available at: www.sanidad.gob.es\/areas\/farmacia\/infoMedicamentos\/valtermed\/docs\/20240219_Protocol_AME.pdf. Accessed April 20 2024."},{"key":"e_1_3_4_35_1","unstructured":"Ministerio de Sanidad. Protocolo farmacocl\u00ednico del tratamiento con onasemnog\u00e9n abeparvovec (Zolgensma\u00ae) en pacientes con atrofia muscular espinal en el sistema nacional de salud; 2024. Available at: www.sanidad.gob.es\/areas\/farmacia\/infoMedicamentos\/valtermed\/docs\/20220408_Protocolo_farmacoclinico_Zolgensma_AME.pdf. Accessed April 20 2024."},{"key":"e_1_3_4_36_1","unstructured":"Ministerio de Sanidad. BIFIMED: Buscador de la Informaci\u00f3n sobre la situaci\u00f3n de financiaci\u00f3n de los medicamentos \u2013 Nomencl\u00e1tor de ABRIL \u2013 2024; 2024. Available at: www.sanidad.gob.es\/profesionales\/medicamentos.do?metodo=verDetalle&cn=730790. Accessed April 20 2024."},{"key":"e_1_3_4_37_1","unstructured":"Managed Access Agreement. Onasemnogene abeparvovec for pre-symptomatic 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the SMN1 gene and up to 3 copies of the SMN2 gene [ID1473]; 2024. Available at: www.nice.org.uk\/guidance\/hst15\/documents\/committee-papers-3. Accessed July 14 2024."},{"key":"e_1_3_4_38_1","unstructured":"Managed Access Agreement. Nusinersen (SPINRAZA\u00ae) for the treatment of 5q spinal muscular atrophy; 2024. Available at: www.nice.org.uk\/guidance\/ta588\/resources\/managed-access-agreement-july-2019-pdf-6842812573. Accessed July 14 2024."},{"key":"e_1_3_4_39_1","unstructured":"Managed Access Agreement. Risdiplam for treating spinal muscular atrophy in children and adults [ID1631]; 2024. Available at: www.nice.org.uk\/guidance\/ta755\/documents\/final-appraisal-determination-document-7. Accessed July 14 2024."},{"key":"e_1_3_4_40_1","unstructured":"Grubert N. Innovative access arrangements and managed entry what Canada can learn from Europe. 2024. Available at: https:\/\/innovativemedicines.ca\/wp-content\/uploads\/2023\/04\/6328_IMC_ME_IAA_Report_v6.pdf. Accessed July 14 2024."},{"key":"e_1_3_4_41_1","unstructured":"CADTH reimbursement recommendation (draft) risdiplam; 2024. Available at: www.cadth.ca\/sites\/default\/files\/cdr\/complete\/SR0661%20Evrysdi%20-%20Draft%20CADTH%20Recommendation%20for%20Posting%20May%2013%2C%202021.pdf. Accessed July 14 2024."},{"key":"e_1_3_4_42_1","unstructured":"CADTH Canadian Drug Expert Committee Recommendation (FINAL) Nusinersen; 2024. Available at: www.cadth.ca\/sites\/default\/files\/cdr\/complete\/SR0525_Spinraza_complete_Dec_22_17.pdf. Accessed July 14 2024."},{"key":"e_1_3_4_43_1","unstructured":"CADTH Canadian Drug Expert Committee Recommendation (FINAL) Onasemnogene abeparvovec; 2024. Available at: www.cadth.ca\/sites\/default\/files\/cdr\/complete\/SG0649%20Zolgensma%20-%20CDEC%20Final%20Recommendation%20March%2026%2C%202021%20for%20posting.pdf. Accessed July 14 2024."},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1542\/neo.20-8-e437"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0671-8"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-802973-2.00013-6"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-020-00624-2"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-021-01328-7"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.4155\/cli.14.52"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-020-00434-z"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204705"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01413-9"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2022.100375"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.11237"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare11030447"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-024-01395-7"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-016-0478-9"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1002\/hec.4112"},{"key":"e_1_3_4_59_1","unstructured":"NewsRARE. Revista de divulgaci\u00f3n cient\u00edfica sobre Enfermedades Raras; 2024. Available at: www.weber.org.es\/wp-content\/uploads\/2022\/01\/nR-Vol-6-num-2-2021-WEB.pdf. Accessed May 5 2024."},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2023.10.017"},{"key":"e_1_3_4_61_1","unstructured":"Reform of the EU pharmaceutical legislation affordable accessible and innovative medicines; 2024. Available at: www.commission.europa.eu\/strategy-and-policy\/priorities-2019-2024\/promoting-our-european-way-life\/european-health-union\/reform-eu-pharmaceutical-legislation_en. Accessed July 15 2024."}],"container-title":["Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/21678421.2024.2400522","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T13:00:13Z","timestamp":1737032413000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/21678421.2024.2400522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,10]]},"references-count":60,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2025,1,2]]}},"alternative-id":["10.1080\/21678421.2024.2400522"],"URL":"https:\/\/doi.org\/10.1080\/21678421.2024.2400522","relation":{},"ISSN":["2167-8421","2167-9223"],"issn-type":[{"value":"2167-8421","type":"print"},{"value":"2167-9223","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,10]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iafd20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iafd20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-06-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-24","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}